Abstract
BackgroundInterleukin-2 (IL-2) is an important immunotherapy cytokine for various diseases including cancer. Some studies reported the efficacy and safety on cisplatin combined with IL-2 versus cisplatin alone for treating malignant pleural effusion (MPE) through thoracic injection.MethodsWe searched these studies from medical electronic database. A total of 18 studies that met the inclusion criteria were recruited in this meta-analysis. Pooled odds ratios (OR) with 95% confidence intervals (CI) were determined by the fixed effects model of meta-analysis.ResultsThe objective response rate (ORR) and disease control rate (DCR) of cisplatin plus IL-2 for controlling MPE was significantly higher than that of cisplatin alone (p < 0.001). In addition, compared with cisplatin alone, the presence of IL-2 improved the quality of life (QOL) of patients with MPE (p < 0.001). Although the use of IL-2 seemed to increase the probability of fever in patients (p = 0.001), it did not lead to extra other side effects (AEs) including myelotoxicity, nausea/vomiting and chest pain (p > 0.05).ConclusionsThe low-dose IL-2 improved the ORR, DCR and QOL of patients in the treatment of MPE. Although it may cause fever in patients, it did not increase other AEs.
Highlights
Interleukin-2 (IL-2) is an important immunotherapy cytokine for various diseases including cancer
A total of 18 studies were recruited in this meta-analysis At first, a total of 263 documents were initially retrieved
The results of meta-analysis showed that the odds ratios (OR) of both was 2.75, which suggested that cisplatin plus IL-2 improved the quality of life (QOL) of patients with malignant pleural effusion (MPE) compared with cisplatin alone (Fig. 3b), responding an absolute 2.75-fold increase
Summary
Interleukin-2 (IL-2) is an important immunotherapy cytokine for various diseases including cancer. Some studies reported the efficacy and safety on cisplatin combined with IL-2 versus cisplatin alone for treating malignant pleural effusion (MPE) through thoracic injection. Some malignancies are often associated with malignant pleural effusion (MPE). IL-2 is a thymus dependent lymphocyte growth factor, which regulates the proliferation and differentiation of lymphocytes [6] It plays a major role in the growth and proliferation of NK and thymus dependent lymphocyte cells, it has been introduced to treat various diseases including cancer [7]. IL-2 has been shown to mediate tumor regression and has been used for treating metastatic renal cell carcinoma and metastatic melanoma [9, 10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
